JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

JPMorgan Chase & Co. increased its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 543.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,315 shares of the company’s stock after acquiring an additional 20,536 shares during the period. JPMorgan Chase & Co. owned about 0.09% of Alto Neuroscience worth $278,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its holdings in shares of Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after purchasing an additional 595,673 shares during the last quarter. Barclays PLC increased its holdings in shares of Alto Neuroscience by 872.7% during the third quarter. Barclays PLC now owns 29,599 shares of the company’s stock worth $339,000 after buying an additional 26,556 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after acquiring an additional 281,018 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Alto Neuroscience in the 3rd quarter worth approximately $124,000. Finally, Wellington Management Group LLP acquired a new stake in Alto Neuroscience during the 3rd quarter valued at $694,000.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Robert W. Baird decreased their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Wedbush downgraded Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.47 on Friday. Alto Neuroscience, Inc. has a twelve month low of $3.56 and a twelve month high of $24.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The business’s fifty day moving average is $4.24 and its 200-day moving average is $8.30.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. Research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.